Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jul 30, 2026 (2 months ago)

Clindamycin Palmitate Hydrochloride for Oral Solution

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR ORAL SOLUTION, USP, 75 mg/5 mL, Rx Only, 100 mL, Distributed by: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, NDC 23155-603-51

Affected NDC 23155-0603-51

Compare with the code on your package — it is the most precise check available.

Drug: Clindamycin Category: Antibiotic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
clindamycin palmitate hydrochloride
NDC 23155-0603
75 mg/5mL Granule, for Solution
Oral
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. Rx
Recalling firm
Heritage Pharmaceuticals Inc
NDC code
23155-603-51
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0768-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Clindamycin recalls

See all

Other recalls by Heritage Pharmaceuticals Inc

All 2026 recalls
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-583-25 D-0112-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-582-01 D-0111-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-581-01 D-0110-2026
Class II · Moderate risk

Desipramine Hydrochloride Tablets

CGMP Deviations: N-Nitroso Desipramine impurity exceeding the permissible acceptable daily intake level.

Ongoing Nitrosamine impurity Heritage Pharmaceuticals Inc NDC 23155-580-01 D-0109-2026